IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 98.02

Change

+0.41 (+0.42)%

Market Cap

N/A

Volume

0.11M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.51 (+0.33%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

+0.25 (+0.35%)

USD 3.01B
FXH First Trust Health Care AlphaD..

+0.83 (+0.75%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.22 (+0.25%)

USD 0.23B
IDNA iShares Genomics Immunology an..

+0.24 (+0.98%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.12 (+0.31%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

+0.57 (+0.60%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.52 (+1.80%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.58 (+0.93%)

USD 0.02B
FTXH First Trust Nasdaq Pharmaceuti..

+0.04 (+0.13%)

USD 0.02B

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.88 % 0.00 %

+0.21 (+0.15%)

USD 1.46B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

+0.07 (+0.15%)

CAD 0.66B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.03% 91% A- 64% D
Dividend Return 0.78% 65% D 15% F
Total Return 13.81% 86% B+ 59% D-
Trailing 12 Months  
Capital Gain 18.25% 50% F 52% F
Dividend Return 1.48% 79% B- 21% F
Total Return 19.74% 55% F 48% F
Trailing 5 Years  
Capital Gain 61.64% 73% C 74% C
Dividend Return 6.33% 68% D+ 20% F
Total Return 67.97% 73% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 7.46% 67% D+ 63% D
Dividend Return 8.42% 67% D+ 58% F
Total Return 0.96% 74% C 22% F
Risk Return Profile  
Volatility (Standard Deviation) 10.69% 95% A 76% C+
Risk Adjusted Return 78.77% 81% B- 89% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike